Long-peptide vaccination with driver gene mutations in p53 and Kras induces cancer mutation-specific effector as well as regulatory T cell responses

Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer

(2017) Ugur Sahin et al.   NATURE

IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial

(2016) Brian I Rini et al.   LANCET ONCOLOGY

Regulatory T Cells Require TCR Signaling for Their Suppressive Function

(2015) Amanda M. Schmidt et al.   JOURNAL OF IMMUNOLOGY

Mutant MHC class II epitopes drive therapeutic immune responses to cancer

(2015) Sebastian Kreiter et al.   NATURE

Tumor-specific cytotoxic T lymphocyte activity determines colorectal cancer patient prognosis

(2014) Christoph Reissfelder et al.   JOURNAL OF CLINICAL INVESTIGATION

The immunological and clinical effects of mutated ras peptide vaccine in combination with IL-2, GM-CSF, or both in patients with solid tumors

(2014) Osama E Rahma et al.   Journal of Translational Medicine

A vaccine targeting mutant IDH1 induces antitumour immunity

(2014) Theresa Schumacher et al.   NATURE

Therapeutic vaccines for cancer: an overview of clinical trials

(2014) Ignacio Melero et al.   Nature Reviews Clinical Oncology

Adjuvants That Improve the Ratio of Antigen-Specific Effector to Regulatory T Cells Enhance Tumor Immunity

(2013) R. Perret et al.   CANCER RESEARCH

Persistent antigen at vaccination sites induces tumor-specific CD8+ T cell sequestration, dysfunction and deletion

(2013) Yared Hailemichael et al.   NATURE MEDICINE

Cancer Genome Landscapes

(2013) B. Vogelstein et al.   SCIENCE

Prospects of combinatorial synthetic peptide vaccine-based immunotherapy against cancer

(2013) Ramon Arens et al.   SEMINARS IN IMMUNOLOGY

HLA Class II tetramers reveal tissue-specific regulatory T cells that suppress T-cell responses in breast carcinoma patients

(2013) Hans-Henning Schmidt et al.   OncoImmunology

Exploiting the Mutanome for Tumor Vaccination

(2012) J. C. Castle et al.   CANCER RESEARCH

Cancer vaccines: should we be targeting patients with less aggressive disease?

(2012) Diane F Hale et al.   Expert Review of Vaccines

Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting

(2012) Hirokazu Matsushita et al.   NATURE

Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival

(2012) Steffen Walter et al.   NATURE MEDICINE

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

(2012) Marco Gerlinger et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tumor antigen specific iTreg accumulate in the tumor microenvironment and suppress therapeutic vaccination

(2012) Taylor H. Schreiber et al.   OncoImmunology

A new era in anticancer peptide vaccines

(2010) Sonia A. Perez et al.   CANCER

Response definition criteria for ELISPOT assays revisited

(2010) Z. Moodie et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Long-term follow-up of patients with resected pancreatic cancer following vaccination against mutant K-ras

(2010) Synne Wedén et al.   INTERNATIONAL JOURNAL OF CANCER

Induction of p53-Specific Immunity by a p53 Synthetic Long Peptide Vaccine in Patients Treated for Metastatic Colorectal Cancer

(2009) F. M. Speetjens et al.   CLINICAL CANCER RESEARCH

Antigen-specific Tregs control T cell responses against a limited repertoire of tumor antigens in patients with colorectal carcinoma

(2009) Andreas Bonertz et al.   JOURNAL OF CLINICAL INVESTIGATION

Vaccination against HPV-16 Oncoproteins for Vulvar Intraepithelial Neoplasia

(2009) Gemma G. Kenter et al.   NEW ENGLAND JOURNAL OF MEDICINE

Accurate approximation method for prediction of class I MHC affinities for peptides of length 8, 10 and 11 using prediction tools trained on 9mers

(2008) C. Lundegaard et al.   BIOINFORMATICS

Self-Tolerance Does Not Restrict the CD4+ T-Helper Response against the p53 Tumor Antigen

(2008) M. M. Lauwen et al.   CANCER RESEARCH

Superior induction of anti-tumor CTL immunity by extended peptide vaccines involves prolonged, DC-focused antigen presentation

(2008) Martijn S. Bijker et al.   EUROPEAN JOURNAL OF IMMUNOLOGY